Participated · Series E · Sep 2023

Tomorrow.io positions itself as the world's leading Resilience Platform, combining a proprietary satellite constellation with a generative AI–integrated forecasting engine to deliver weather intelligence. The company says it operates a fully operational proprietary satellite constellation and leverages next-generation space technology, advanced AI, and proprietary weather modeling. Tomorrow.io is deploying DeepSky, described as the world's first AI-native weather satellite constellation, and aims to expand its space-based observation network. Its platform is used to provide real-time, actionable resilience intelligence and is trusted by six of the top ten Fortune 500 companies. The company has been recognized as a TIME 100 Most Influential Company and a Fast Company Most Innovative Company. The recent expansion of its Series F to $210 million is intended to accelerate its AI capabilities and further develop its agentic platform.

Participated · Equity · Jan 2022

MeMed develops rapid host immune-response diagnostic tests that decode the body’s immune signals to help clinicians distinguish bacterial from viral infections and predict COVID-19 severity. The company’s MeMed BV® test received FDA clearance for use on the point-of-need MeMed Key® platform to aid in distinguishing bacterial and viral infections in children and adults. MeMed also markets the MeMed COVID-19 Severity™ test, which has been cleared for use in Europe. The company says it will use new funding to scale manufacturing, accelerate commercialization and expand its host-response product portfolio, with a particular operational focus on the U.S. MeMed reports total funding now exceeds $200 million, including prior support from the U.S. Department of Defense and the EU Commission. The company maintains a presence in Haifa, Israel and Boston, MA. MeMed has developed and validated an immune-based protein signature called MeMed BV™ to distinguish between bacterial and viral infections. The company is also completing development of MeMed Key™, a point-of-care protein measurement platform, and plans to upscale manufacturing and seek clearance for that device. MeMed intends to expand its pipeline of tests that integrate machine learning with immune-based measurements to address major clinical challenges. The company is led by co‑founders Dr. Eran Eden (CEO) and Dr. Kfir Oved (CTO). MeMed completed an over $70M financing round to support market adoption, product development, manufacturing scale-up, regulatory clearance efforts, and pipeline expansion. MeMed develops host-response diagnostics built on its ImmunoXpert platform, which measures a three-protein signature (TRAIL, IP-10 and C-reactive protein) to differentiate bacterial and viral infections. The technology has been validated in large studies but cannot identify exact pathogen strains. The current instrument requires about two hours and a trained technician, limiting emergency-room use. Co-founders CEO Eran Eden and CTO Kfir Oved are developing a second-generation benchtop device that would use the same three proteins and algorithm to deliver results in under 15 minutes from a drop of blood and be plug-and-play. MeMed's stated clinical goal is to right-size antibiotic use to reduce inappropriate prescriptions and slow antibiotic resistance. The company received DTRA funding to accelerate development of the faster, easier-to-use instrument.

Participated · Series D · Sep 2021

Lightricks develops a suite of more than a dozen subscription-based photo- and video-editing apps across iOS and Android, anchored by Facetune and newer tools like Facetune Video and Videoleap. The company serves a creator and marketing audience, offering tools for individual creators, online marketers and small businesses. Across its apps Lightricks reports 29 million monthly active users, over 5 million paid subscribers and roughly 78 million monthly exports. In 2021 the company was on track for over $200 million in revenue and planned to grow that figure by about 40% the following year. To drive that growth it is shifting strategy toward M&A to become a one-stop creator platform and is investing in in-house product and content initiatives. Lightricks planned headcount expansion from 460 employees with 60 hires in 2021 and a longer-term goal of 1,000 employees by the end of 2023, and intends to expand teams in Haifa, London and Shenzhen. Lightricks builds consumer and enterprise content-creation apps, including Facetune, the Enlight suite of photography tools, and Swish, an enterprise-focused marketing video editor. The company operates three divisions supporting six products and about 260 employees. Its apps have been downloaded roughly 180 million times and the company reports roughly 3 million total subscribers (Facetune ~1M, Enlight ~1M, plus Swish subscribers). Lightricks began offering subscription layers in 2015 and was seeing about $10 million in annual revenue that year. The team, originally founded by five PhD students and led by CEO Zeev Farbman, says it is developing more subscription-based content-creation apps and continues longer-term R&D projects slated two to three years out. The company plans product development and strategic acquisitions funded by recent financing. Lightricks designs and develops content-creation mobile apps led by co-founder and CEO Dr. Zeev Farbman, with flagship products such as Facetune and the Enlight Creativity Suite. The company’s apps have about 100 million downloads worldwide and nearly 1 million subscribers. Its most recent app, Enlight Pixaloop, reached over 6 million users and nearly 200,000 paying subscribers within two months of release. Since its first investment in 2015 the team has grown from 30 to 150 employees, and the company projects revenue to exceed $100 million in 2019. Lightricks plans to build more products and double headcount, recruiting to a total of 300 employees across its Jerusalem and London offices. The company intends to use new funding partly for a secondary transaction to acquire shares from founders, employees, and investors and partly to fund product and team expansion. Lightricks develops mobile image-processing and photo-editing apps best known for Facetune and Enlight. The Jerusalem-based company sells its apps (Facetune and Enlight priced at $3.99) and says it has sold over five million copies. It reports a yearly revenue run rate of $10 million and has been profitable using a self-described "bakery model" of directly selling paid apps. Founded in 2013, the company has about 30 employees and was bootstrapped until this financing. New capital will be used to continue improving Facetune and Enlight, launch new products, and to double the team over the next year. Co-founder and CEO Zeev Farbman says the firm focuses on bringing research-level algorithms to mobile creativity tools.

Participated · Series C · Mar 2021

Veev Group, Inc. announced a preferred-stock financing on March 22, 2021 that generated aggregate gross proceeds of $106,277,481.3326. The company issued 169,913,325 Series C preferred shares at $0.619 per share (gross proceeds $105,176,348.175) and 2,223,613 Series C-1 preferred shares at $0.4952 per share (gross proceeds $1,101,133.1576). The Series C and Series C-1 shares carry non‑cumulative fixed dividends of $0.03095 and $0.02476 per share per annum, respectively. Both series are convertible into common shares at fixed conversion prices of $0.619 and $0.4952 per share, respectively. The round was raised at a post‑money valuation of $153,728,394 and included participation from More Investment House Ltd., Migdal Insurance and Financial Holdings Ltd., Psagot Investment House Ltd., Shavit Capital and other investors. The company has raised nearly $200,000,000 in funding to date. Veev Group develops integrated real estate solutions centered on its Veev panelized building system, which uses light gauge steel framing, high-performance acrylic surfaces and millwork, radiant climate control, and a digital home ecosystem. The company is focused on high-performance multifamily and accessory dwelling unit (ADU) products for the San Francisco Bay Area. Its current development pipeline totals more than 230 units and 620,000 gross building square feet. Veev employs more than 260 team members and operates a headquarters and fabrication facility in the San Francisco Bay Area, with an additional office in Tel Aviv. The company was originally established in 2008 and consolidated its subsidiaries in 2019 to accelerate innovation in residential housing.

Participated · Series B · Jun 2020

Alpha Tau Medical is a Tel Aviv–based medical device company developing Alpha DaRT, an alpha-radiation therapy for solid tumors. Founded in 2016 and led by CEO Uzi Sofer, the company is conducting clinical trials in multiple indications worldwide, including its first U.S. trial at Memorial Sloan Kettering, a pancreatic cancer trial at CHUM in Montreal, and studies at three academic institutions in Japan. The company recently closed funding to support continued clinical development of Alpha DaRT. It is establishing new global manufacturing facilities in Israel and elsewhere and is in the process for CE marking for its first indication. The funds will be directed toward clinical development and related commercialization efforts. Alpha Tau Medical, founded in 2016 by Uzi Sofer, is advancing Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy), an alpha-radiation treatment for solid tumors. Alpha DaRT delivers high-precision alpha radiation released when radioactive substances decay inside the tumor; short-range alpha particles kill cancer cells while sparing surrounding healthy tissue. The company has started clinical trials with research centers worldwide using different protocols across indications including pancreatic, breast, head and neck, gynecological and prostate cancers. Alpha Tau has established subsidiaries in the USA and Japan and is forming further collaborations to optimize local distribution and manufacturing. The company plans to use new funds to explore Alpha DaRT in clinical trials globally and to establish production facilities for radioactive DaRT seeds to meet local distribution demand. The DaRT technology was invented in 2003 by Prof. Itzhak Kelson and Prof. Yona Keisari and was originally patented by Ramot, which became a shareholder of Alpha Tau Medical. Alpha Tau Medical develops Alpha DaRT (Diffusing Alpha-Emitters Radiation Therapy), an implanted alpha-radiation treatment for solid tumors that was developed since 2003 at Tel Aviv University. Preclinical testing involved over 6,000 animals across numerous studies showing effectiveness and safety in various tumor indications and anatomical areas. Preliminary results from its first clinical study indicate the technology can effectively destroy solid tumors with no systemic adverse events. The treatment is delivered by inserting the device directly into the tumor under local anesthesia, requires about 60 minutes, and does not need special shielding or capital equipment. Alpha Tau plans to further develop Alpha DaRT for 11 different types of solid tumors and to expand clinical programs internationally. The company raised a second funding round of undisclosed amount to support further development and clinical studies.